drugset / Trial / NCT02419508
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
Timeline
- Start
- 2015-08-07
- Primary completion
- 2018-02-27
- Completion
- 2018-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Small molecule | 0.2 % | Other |
| Subject | Brinzolamide | Small molecule | 1 % | Other |
| Background | Bimatoprost | Other / unclassified | 0.01 % | Other |
| Background | Latanoprost | Small molecule | 0.005 % | Other |
| Background | Travoprost | Other / unclassified | 0.004 % | Other |